Description
Key facts
Cell type:HEK-293T,
Species or organism:Human,
Tissue:Kidney,
Knockout validation:Sanger Sequencing,Western blot,
Mutation description:Knockout achieved by using CRISPR/Cas9, 4 bp deletion in exon 2 and 5 bp deletion in exon 2.
Product details:
Knockout cell lysate achieved by CRISPR/Cas9.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation:
Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10).
This means that the protein of interest is denatured.
If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions:
Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our
limited use license
patent pages
Properties and Storage Information:
Gene name-CELF1, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Western blot, Shipped at conditions-Ambient - Can Ship with Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C
Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
CUG-BP1 also known as CELF1 belongs to the CELF family of RNA-binding proteins. It is a 52-kDa protein expressed across various tissues with noticeable levels in heart and skeletal muscle. CUG-BP1 regulates alternative splicing by binding to specific CUG triplet repeats in RNA molecules. This binding influences the processing of pre-mRNAs impacting gene expression at the post-transcriptional level.
Biological function summary
The regulation by CUG-BP1 affects both mRNA stability and translation. The protein plays an important role in managing the expression of genes involved in muscle differentiation and development. CUG-BP1 often interacts with other cellular machinery forming functional complexes to facilitate its role in RNA metabolism. Its capacity to bind CUG motifs on target RNA highlights its significance in cellular processes.
Pathways
CUG-BP1 participates in pathways influencing muscle formation and maintenance. It plays part in the regulation of alternative splicing processes critical for efficient functioning of the p38 MAPK pathway. This pathway connects CUG-BP1 to other RNA-binding proteins and kinases. By doing so it affects different transcriptional and post-transcriptional processes emphasizing its critical function in cellular maintenance.
CUG-BP1 has been linked to myotonic dystrophy type 1 (DM1) and certain cancers. In DM1 the protein becomes sequestered by expanded CUG repeats in RNA disrupting its normal function. This sequestration leads to misregulated splicing events affecting various cellular functions. CUG-BP1’s interaction with other proteins such as MBNL1 further elucidates its role in disease pathogenesis highlighting its importance in understanding RNA-mediated disorders.
